Skip to main content

AstraZeneca says working with regulators on best approach to lower dose regimen

     

(Reuters) - AstraZeneca is working with regulators to investigate a lower dosage of its vaccine that performed better than a full dosage, a spokesman for the company said, after its chief executive was quoted as saying an additional global trial was likely.

Asked about the Bloomberg report on the additional trial, a spokesman for AstraZeneca said: "As we communicated earlier this week, there is strong merit in continuing to further investigate the half-dose/full dose regimen."

"We are further evaluating the data and will work with regulators on the best approach for further evaluation. This would add to data from existing trials which are currently being prepared for regulatory submission," he said.

Comments

Popular posts from this blog

What you need to know about the latest Barrister (Esq Obia Sunday)

Melissa Stockwell lost Her Leg in the Iraq War,now she has her sights set on the Tokyo paralympics

BREAKING NEWS: MESSI LEAVES BARCELONA

Young Student who Had Taken Fowl to School to Pay up his Debt of N128k Gets Scholarship.

UNN ASUU, residents urge FG to prevent another strike

Tambuwal urges ASUU to devise other means of industrial action, not strikes

I did 2 days rituals for community, Nigeria’s peace, progress — Traditional ruler

Little story of The latest Barrister Esq Alasa Blessing

Biden snubs Buhari in first calls to Africa